Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City.
AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005834/en/
Contacts
Savara Inc. IR & PR
Anne Erickson
Senior Vice President, Chief of Staff
anne.erickson@savarapharma.com
(512) 851-1366
Source: Savara Inc.
View this news release online at:
http://www.businesswire.com/news/home/20220601005834/en
